Revvity/$RVTY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Revvity
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Ticker
$RVTY
Sector
Primary listing
NYSE
Employees
11,000
Headquarters
Website
Revvity Metrics
BasicAdvanced
$11B
38.53
$2.37
0.95
$0.28
0.31%
Price and volume
Market cap
$11B
Beta
0.95
52-week high
$128.29
52-week low
$81.36
Average daily volume
1.3M
Dividend rate
$0.28
Financial strength
Current ratio
3.329
Quick ratio
2.46
Long term debt to equity
44.661
Total debt to equity
44.664
Dividend payout ratio (TTM)
11.88%
Interest coverage (TTM)
4.59%
Profitability
EBITDA (TTM)
840.062
Gross margin (TTM)
55.93%
Net profit margin (TTM)
10.19%
Operating margin (TTM)
15.08%
Effective tax rate (TTM)
11.80%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
2.05%
Return on equity (TTM)
3.61%
Valuation
Price to earnings (TTM)
38.528
Price to revenue (TTM)
3.926
Price to book
1.4
Price to tangible book (TTM)
-6.81
Price to free cash flow (TTM)
21.842
Free cash flow yield (TTM)
4.58%
Free cash flow per share (TTM)
4.175
Dividend yield (TTM)
0.31%
Forward dividend yield
0.31%
Growth
Revenue change (TTM)
3.33%
Earnings per share change (TTM)
72.56%
3-year revenue growth (CAGR)
-9.28%
10-year revenue growth (CAGR)
2.25%
3-year earnings per share growth (CAGR)
-24.24%
10-year earnings per share growth (CAGR)
5.10%
What the Analysts think about Revvity
Analyst ratings (Buy, Hold, Sell) for Revvity stock.
Bulls say / Bears say
Revvity exceeded Q1 estimates with adjusted EPS of $1.01 versus $0.95 and revenue of $664.8 million versus $661.2 million, supported by consistent biotech demand, and raised its 2025 revenue guidance to $2.83 billion–$2.87 billion (Reuters).
For Q2 2025, Revvity reported adjusted EPS of $1.18, beating the $1.14 consensus, and revenue of $720.3 million, above the $710.4 million estimate, demonstrating strong operational performance (Barron’s).
More than half of Revvity’s revenue comes from international markets, and a weaker U.S. dollar gave a foreign exchange boost that helped justify its increased revenue outlook (Reuters).
Revvity’s Q2 adjusted operating margin fell to 26.6% from 28.8% year-over-year, indicating profitability is under pressure from higher costs (Barron’s).
The company lowered its full-year adjusted EPS guidance to $4.85–$4.95 from the previous $4.90–$5.00, coming in below the analyst consensus of $4.93, pointing to potential earnings headwinds (Barron’s).
Revvity highlighted a “meaningful pullback” in its immunodiagnostics business in China after DRG-related reimbursement changes triggered a double-digit sales drop, which caused shares to fall nearly 10% (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Revvity Financial Performance
Revenues and expenses
Revvity Earnings Performance
Company profitability
Revvity News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Revvity stock?
Revvity (RVTY) has a market cap of $11B as of October 08, 2025.
What is the P/E ratio for Revvity stock?
The price to earnings (P/E) ratio for Revvity (RVTY) stock is 38.53 as of October 08, 2025.
Does Revvity stock pay dividends?
Yes, the Revvity (RVTY) stock pays dividends to shareholders. As of October 08, 2025, the dividend rate is $0.28 and the yield is 0.31%. Revvity has a payout ratio of 11.88% on a trailing twelve-month basis.
When is the next Revvity dividend payment date?
The next Revvity (RVTY) dividend payment is scheduled for November 07, 2025.
What is the beta indicator for Revvity?
Revvity (RVTY) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.